Cancer and Metastasis Reviews

Papers
(The H4-Index of Cancer and Metastasis Reviews is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer252
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions129
Regulation of dormancy during tumor dissemination: the role of the ECM115
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities106
Clonal tracking in cancer and metastasis82
The functions and modifications of tRNA-derived small RNAs in cancer biology82
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression79
Obesity and cancer73
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective61
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms58
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?54
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations53
CAR T-cell therapy to treat multiple myeloma: current state and future directions53
Targeting lipid metabolism in cancer: neuroblastoma52
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor51
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer50
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond47
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review44
p73 isoforms meet evolution of metastasis42
Cell-cell interactions mediating primary and metastatic breast cancer dormancy41
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?40
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives39
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients38
Biography—Mathieu Boissan, Pharm.D., Ph.D37
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer36
Preface36
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance33
Biographies32
Neuropeptide Y in cancer—biological functions and potential clinical implications32
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications31
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance30
0.035904884338379